Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Broker's call: Reliance Securities - Tata Elxsi (Buy)

2018-08-09 thehindubusinessline
TEL’s revenue rose 1.8 per cent q-o-q in 1QFY19, with the key SDS business clocking 2.5 per cent q-o-q growth; y-o-y SDS revenue growth was a robust 19.6 per cent, the fastest growth since 1QFY17. EBITDA margin rose 255 bps q-o-q and 516 bps y-o-y on operating leverage and cost control to 27.9 per cent, its highest-ever level.
500408 TATAELXSI 500570 TATAMOTORS TTM

0
Tata Elxsi Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Shareholders meeting

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Shareholders meeting

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Shareholders meeting

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Resignation

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
Tata Elxsi Limited - Appointment

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
An evening walk down Dalal Street | Sensex ends at record closing high, Nifty below 11,150; midcaps give up all gains

2018-07-25 moneycontrol
It was an anti-climax of sorts on the market as benchmarks failed to clock fresh highs, particularly for the Nifty as they managed to end the day on a mildly higher note. The Sensex, however, has ended at a record closing high. This is the sixth time in the last 10 trading sessions that the index has achieved this feat.
532553 INDIGO 500408 590003 TATAELXSI KARURVYSYA 539448 WELENT

0
Tata Elxsi hits record high, up 7% after strong operating margin in Q1

2018-07-25 moneycontrol
Tata Elxsi share price hit all-time high of Rs 1,477.10, rising 7 percent intraday on Wednesday following strong operating profit for the quarter ended June 2018.
500408 TATAELXSI

0
Tata Elxsi Limited - Financial Result Updates

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500408 TATAELXSI

0
BHEL, Canara Bank, L&T, JSW Steel results

2018-07-24 thehindubusinessline
Over 50 firms will declare their April-June quarter results on Wednesday. Among these are Ambuja Cements, BHEL, Bharat Bijlee, Bharati Infratel, Canara Bank, Chemfab Alkalies, CG Consumer, Dishman Carbogen, Gruh Finance, HCL Infosys, Hero MotoCorp, India Grid, Ind-Swift, IRB infra, JSW Steel, Jubilant Food, Jyothy Labs, Karur Vysya Bank, L&T, Omaxe, PVR, RECL, Sanofi India, Shriram City Union, SKF India, Tata Elxsi, TTK Prestiege, United Bank and Welspun Enterprises.
SANOFI 500408 500425 590003 UDBKL 500228 UBLS AMBUJACEM 511288 WELENT 532483 AMBUY UBLA SKFINDIA 500674 HEROMOTOCO 503960 500472 GRUH GRHFY JSWSTEEL CNRYY 500182 532553 BBL TATAELXSI HRTQY KARURVYSYA CANBK

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...